MET 10-K Analysis: The $2,964M Gap Between Two P/E Ratios

MetLife, the largest U.S. life insurer with $77 billion in annual revenue, reported a 25% decline in net income for FY 2025 — to $3.17 billion. In the same filing, adjusted earnings grew 10% to $6.14 billion. The $2,964M gap between these two numbers isn't an error. It's the defining structural feature of a company that manages $745 billion in assets, hedges with derivatives that generate billions in non-cash mark-to-market swings, and remeasures insurance liabilities every quarter under LDTI accounting.

The FY2025 10-K, filed February 19, 2026, presents two legitimate versions of MetLife's earnings — and two valid P/E ratios for the same stock: 16.7x on GAAP earnings or 8.9x on adjusted earnings. Whether MetLife is expensive or deeply cheap depends entirely on which number an investor uses. Every earnings summary repeated the -25% net income headline and the +10% adjusted EPS growth, but none decomposed the $2,964M bridge to understand which adjustments are permanent accounting noise and which represent genuine earnings quality risk.

The filing reveals that the standard bull-bear framework fails here. The bull case ("8.9x adjusted P/E is cheap!") ignores that 26% of adjusted earnings depend on a single assumption — 9% private equity returns. The bear case ("-25% net income decline!") ignores that MetLife simultaneously generated $17.1 billion in operating cash flow, a 5.39x ratio to reported net income. Only by decomposing the bridge component by component — rating each for persistence and controllability — can an investor determine how much of the $2,964M gap is noise and how much is signal.

The $2,964M Illusion: How MetLife Became a Dual-Identity Stock

GAAP and adjusted earnings tell opposite stories about MetLife. GAAP says net income fell 24.9% to $3.17B — a company in decline. Adjusted metrics say earnings grew 2.4% to $6.14B and adjusted EPS rose 10% to $8.89 — a company thriving. Neither is wrong, and the difference isn't accounting trickery. It's the structural reality of managing a $745 billion asset base in a volatile interest rate environment.

The standard approach is to pick a side — trust GAAP or trust management's adjusted metrics. This article introduces a third framework: Adjustment Bridge Persistence Analysis, which rates each component of the $2,964M gap on two dimensions — will it recur (persistence), and can management influence it (controllability)?

The result is revealing. Approximately $2.3B of the $2,964M gap (78%) comes from high-persistence, low-controllability items — derivative losses and hedge accounting mismatches that will recur in any year with meaningful rate movements. These are genuine accounting noise. The remaining $650M (22%) — primarily net investment losses and MRB gains — represents semi-predictable items where management has partial influence over portfolio positioning and actuarial assumptions. This is the portion that represents actual earnings quality risk.

The cash flow statement provides an independent check on which version of MetLife is real. Operating cash flow reached $17.09B — growing 17.1% while GAAP net income shrank 24.9%. The OCF-to-net-income ratio of 5.39x is extreme even for a life insurer, confirming that the GAAP earnings decline is a mark-to-market phenomenon, not an operational one.

"The ratio of free cash flow of all holding companies to consolidated adjusted earnings available to common shareholders was 82% for 2025 and 79% for 2024."

The 82% FCF-to-adjusted-earnings ratio exceeded management's own 65-75% target, and it improved from 79% in 2024. But a footnote reveals the ratio jumps to 126% when including $1.2B from "other MetLife holding companies" — a source that swung from negative $23M the prior year. That $1.22B swing is unexplained in the filing and should be treated skeptically until management clarifies the source.

The interest rate sensitivity quantified in the MD&A makes the gap's persistence concrete. A 50bps rate decline reduces adjusted earnings by a cumulative $283M over three years — but the GAAP derivative impact swings $253M in a single year, roughly 6-7x the annual adjusted earnings effect. This asymmetry explains why MetLife's GAAP earnings are nearly unpredictable while adjusted earnings remain relatively stable. MetLife's $2,964M GAAP-to-adjusted earnings gap — composed of $1,939M in derivative losses and $1,145M in investment losses — creates two valid P/E ratios for the same stock: 16.7x on GAAP or 8.9x on adjusted earnings.

Growth Without Profit: The PRT Revenue Distortion

MetLife's 8.6% revenue growth headline masks a critical quality problem. The growth engine is pension risk transfers — large-scale transactions where corporations offload their pension obligations to MetLife's balance sheet. Record $14.2B in PRT volume drove RIS segment premiums up 44%, from $8,034M to $11,569M. But the nature of PRT revenue is fundamentally different from MetLife's other businesses.

PRT revenue is recognized upfront as premiums when the deal closes, not amortized through investment income over time. This is why RIS premiums surged 44% while RIS net investment income grew only 3.4% ($8,482M to $8,774M). The $3.5 billion in incremental premiums generated only $292M in incremental NII — confirming that PRT profitability runs through policyholder benefits, not investment spread, and operates at significantly thinner margins than MetLife's core businesses.

The company-level numbers tell the same story. Despite 8.6% revenue growth, operating margin declined 42 basis points to 7.79%. The incremental operating margin — how much profit each new revenue dollar generates — was just 2.3%. That means 97 cents of every new dollar of PRT-driven revenue was consumed by costs, leaving less than 3 cents of incremental operating profit.

Management's own targets hint at awareness of this dynamic. The "New Frontier" efficiency initiative targets a direct expense ratio of 12.1% in 2026 declining to 11.3% by 2029 — an 80 basis point improvement that could generate approximately $616M in annual savings on MetLife's $77B revenue base. But expense ratio improvement is a margin defense, not a growth strategy. It won't solve the structural problem that PRT transactions inflate the top line while diluting average profitability.

The capital return program provides a more reliable floor. MetLife returned $4.4 billion to shareholders in FY2025 — $1.51B in dividends and $2.88B in buybacks — yielding 8.3% in total shareholder return. Share count fell 4.9% to 655.3 million, converting -24.9% net income decline into -20.7% EPS decline. MetLife's record $14.2B in pension risk transfer sales drove RIS premiums up 44% but produced an incremental operating margin of just 2.3%, meaning 97 cents of every new revenue dollar was consumed by costs.

MetLife's Hidden $938M Fee Machine

The Q4 2025 Strategic Reorganization did more than shuffle org charts — it broke out MetLife Investment Management (MIM) as a standalone segment for the first time, giving investors visibility into a fee-based asset management business hidden inside the insurance conglomerate. MIM manages over $600 billion in assets, including MetLife's own general account and third-party mandates, and generated $938M in revenue at a 21.3% adjusted margin — the highest of any MetLife segment by a wide margin.

The 29.4% revenue growth ($725M to $938M) makes MIM look like a breakout growth story. But the filing contains a critical disclosure that changes the interpretation.

"In the fourth quarter of 2025, MetLife completed the Strategic Reorganization... In conjunction with the Strategic Reorganization, effective January 1, 2025, the Company amended agreements between MIM and other MetLife entities to manage general account investments at current market rate fees, a change from 2024 and 2023."

Prior to 2025, MIM's internal fee agreements with other MetLife entities were below market rates — effectively subsidizing the insurance segments at MIM's expense. The repricing to "current market rate fees" means some of the $213M revenue increase ($725M to $938M) is a pricing step-change, not organic asset gathering. The filing does not disclose what fraction is repricing versus organic growth, making it impossible to calculate MIM's true organic growth rate. The 29.4% headline is an upper bound.

This matters for valuation because fee-based asset management businesses trade at dramatically higher multiples than insurance underwriting. If MIM were valued independently at even a conservative 10x revenue, it would represent $9.4B — roughly 18% of MetLife's current $52.8B market cap — from a segment that generates 1.2% of revenue. The market hasn't given MetLife credit for MIM yet, and the Strategic Reorganization is management's explicit signal that they want that credit.

The complication is a mirror image on the cost side. Corporate & Other losses tripled from -$117M to -$293M in FY2025, a $176M deterioration that coincides suspiciously with the Strategic Reorganization. Costs previously embedded in operating segments may now be allocated to Corporate & Other, flattering segment margins while concentrating drag in a single line item. MetLife Investment Management generated $938M in revenue at a 21.3% adjusted margin — the company's highest — but the 10-K reveals that prior-year fees were below market rates, inflating the 29.4% growth rate beyond organic levels.

The Variables That Define the Real MetLife

The difference between "value stock" and "value trap" for MetLife hinges on two swing factors outside management's core operating control. Both are quantified in the filing, and both sit in the portion of the business that determines whether the 8.9x adjusted P/E is a bargain or an illusion.

The first factor is variable investment income. Management targets $1.6 billion in pre-tax variable investment income for 2026 — representing 26% of consolidated adjusted earnings.

"Assuming (i) interest rates follow the observable forward yield curves as of December 31, 2025, including a 10-year U.S. Treasury rate of 4.40% at December 31, 2026, (ii) S&P 500 equity index annual return of 5%, and (iii) private equity annual returns of 9% in 2026 which would contribute to $1.6 billion (pre-tax) of total estimated variable investment income for full year 2026."

The 9% private equity return assumption is the critical input. If PE returns average 5% instead of 9%, approximately $700M in variable investment income is at risk — reducing adjusted EPS from approximately $8.89 to approximately $7.85 and inflating the adjusted P/E from 8.9x to 10.3x. A quarter of the earnings base that makes MetLife look "cheap" depends on a single return assumption in a single asset class.

The second factor is the accelerating deterioration in Corporate & Other. This segment's losses tripled from -$117M to -$293M, and the filing points directly at the cause.

"Our long-term care business experiences gross margin compression as we cannot reduce interest crediting rates for established claim reserves."

Long-term care is an embedded interest rate put option that MetLife wrote decades ago. In a declining rate environment, LTC reserves increase because claim discount rates fall, but the crediting rates on existing claims cannot be lowered. If the -$117M to -$293M trajectory continues toward -$450M, it would erode approximately $150M per year from adjusted earnings, further weakening the value case.

The balance sheet adds a third dimension. Reported debt is $355M, but true obligations total approximately $5.4B when including $3.2B in junior subordinated debentures (6.4-7.875% rates, maturing 2036-2039), $887M in pension underfunding ($8,440M obligation versus $7,553M in plan assets), and approximately $1.0B in unfunded nonqualified pension plans. Additionally, Chariot Holding Company — a Bermuda-registered limited partnership — has redacted investment amounts and unfunded contingent capital commitments, making its materiality impossible to assess.

The AOCI catch-22 ties it all together. MetLife's -$18.1B in accumulated other comprehensive losses means rates can never simultaneously improve both book value and earnings. If rates fall, AOCI reverses and adjusted book value ($70.95 per share versus stated $43.33) converges toward market price — but earnings suffer $283M in cumulative drag over three years. If rates rise, earnings improve by $298M cumulatively, but book value deteriorates further. At 1.11x adjusted book, the stock is near tangible asset value regardless of direction. MetLife's adjusted earnings depend on $1.6B in variable investment income assuming 9% private equity returns — meaning 26% of the earnings base that produces the "cheap" 8.9x P/E ratio hinges on a single return assumption.

What to Watch: The Metrics That Define MetLife's Real Value

At $78.94, MetLife trades at 8.9x adjusted earnings — implying zero growth for a company that grew adjusted EPS 10% in FY2025. The market's skepticism may reflect awareness of the two swing factors — PE return dependency and Corporate & Other deterioration — rather than ignorance of the adjusted metrics. Whether the skepticism is warranted depends on what happens next.

Variable investment income is the single highest-leverage metric. Management targets $1.6B for FY2026. If Q1 comes in below $300M (implying a full-year shortfall), the adjusted earnings base is degrading and the 8.9x P/E re-rates higher. If it tracks at $400M per quarter, the value case strengthens materially.

Corporate & Other losses are the canary. The -$117M to -$293M trajectory needs to stabilize. If Q1 2026 shows losses accelerating toward a -$400M annual run rate, LTC margin compression is worsening faster than expected. If losses moderate toward -$250M annually, the Strategic Reorganization's cost reallocation is stabilizing.

Adjusted EPS should run approximately $2.00-$2.25 in Q1 (FY2025 average of $2.22/quarter, minus typical Q1 seasonality, plus approximately 1.2% per-share buyback uplift). Below $1.90 breaks the double-digit growth narrative. Above $2.30 confirms it.

Direct expense ratio is the test of the New Frontier initiative. Management targets 12.1% for 2026. Any commentary flagging delays or cost overruns weakens the $616M savings opportunity and removes the primary margin expansion lever.

At $78.94, the market implies MetLife's adjusted earnings won't grow — a no-growth valuation for a company generating $17.1B in OCF, buying back 5% of its shares annually, and targeting $25B in five-year free cash flow. The filing supports a value case: MIM provides a high-quality earnings stream growing at 21.3% margins, the 8.3% total shareholder yield is among the highest in insurance, and the FCF yield of 9.5% on the five-year target suggests substantial returns even without multiple expansion. But the filing also complicates it: 26% of adjusted earnings hinge on PE returns, Corporate & Other losses are accelerating, and $5.4B in hidden obligations create more leverage than the balance sheet suggests.

The value-trap test is straightforward: if both PE returns disappoint and Corporate & Other losses accelerate, the 8.9x adjusted P/E inflates to 10-11x on shrinking earnings — fair value at best. If both hold, MetLife is a capital return machine trading at a significant discount to its adjusted earnings power.

Frequently Asked Questions

Why did MetLife's net income drop 25% while revenue grew nearly 9%?

MetLife's GAAP net income fell 24.9% to $3.17B primarily because of $2,964M in non-cash accounting adjustments — derivative losses ($1,939M), investment losses ($1,145M), and hedge accounting mismatches ($410M), partially offset by $508M in MRB gains. These mark-to-market fluctuations are structural features of managing a $745B asset base, not signs of operational deterioration. On an adjusted basis, MetLife's earnings actually grew 2.4% to $6.14B, and adjusted EPS grew 10% to $8.89 due to share buybacks. Operating cash flow simultaneously grew 17.1% to $17.09B, confirming the underlying business generates more cash, not less.

What is MetLife's real P/E ratio?

MetLife trades at 16.7x GAAP earnings ($78.94 / $4.71 GAAP EPS) or 8.9x adjusted earnings ($78.94 / $8.89 adj EPS). The $2,964M gap between these measures represents 48% of adjusted earnings, composed primarily of derivative and investment mark-to-market losses that recur in any rate-volatile environment. Analysis of the bridge components shows approximately 78% ($2.3B) is high-persistence, low-controllability accounting noise, while approximately 22% ($650M) represents semi-predictable items with genuine earnings quality implications. The adjusted P/E of 8.9x is more representative of operating economics, but investors should haircut for the $1.6B in variable investment income dependent on 9% PE returns.

How important are pension risk transfers to MetLife's growth?

PRT deals are MetLife's primary revenue growth engine. Record $14.2B in PRT volume drove RIS premiums up 44% ($8,034M to $11,569M), contributing most of the company's 8.6% revenue growth. However, PRT is a high-volume, low-margin business — RIS segment margin is only 7.9%, below the company average. The incremental operating margin on MetLife's revenue growth was just 2.3%, meaning each new dollar of PRT revenue generates less than 3 cents of operating profit. PRT transactions are also lumpy and episodic — $14.2B in one year does not guarantee similar volumes going forward.

What is MetLife Investment Management and why does it matter?

MIM is MetLife's asset management division, broken out as a standalone segment in Q4 2025's Strategic Reorganization. It manages over $600 billion in assets and generated $938M in revenue (+29.4%) at 21.3% margins — the highest of any MetLife segment. However, part of the growth is artificial: the filing reveals internal fee agreements were amended to market rates starting 2025, after being subsidized in prior years. MIM matters because fee-based asset management commands higher valuation multiples than insurance underwriting — MetLife is signaling it wants credit for this business. At even a conservative 10x revenue, MIM would be worth $9.4B, approximately 18% of MetLife's market cap.

How does MetLife compare to Aflac?

MetLife has 4.5x the revenue ($77.1B vs $17.2B) but dramatically lower margins (net margin 4.1% vs 21.2%) due to its diversified model including capital-intensive PRT. ROTCE is actually higher at MetLife (17.6% vs 13.2%) because -$18.1B in AOCI distorts book value. Both companies have similar shareholder yields (approximately 8%) and GAAP P/E ratios (approximately 16x). The key differentiator: MetLife's $2,964M GAAP-to-adjusted gap has no equivalent at Aflac, where reported earnings track operations more closely. MetLife's FCF margin (22.2% vs 14.9%) is substantially higher from insurance float advantages.

What is MetLife's AOCI catch-22 and how does it affect investors?

Accumulated Other Comprehensive Income stood at -$18.1B, representing unrealized losses on MetLife's fixed-income portfolio from rising rates. This creates a paradox: if rates fall, AOCI reverses and book value surges (adjusted book value is approximately $70.95 vs stated $43.33), but adjusted earnings get hurt — the filing quantifies this at -$283M cumulative over three years for a 50bps decline. If rates rise, earnings improve (+$298M cumulative) but book value deteriorates further. MetLife can never simultaneously improve both metrics. At 1.11x adjusted book value, the stock is near tangible asset value, providing downside support regardless of rate direction.

What hidden obligations does MetLife have beyond its balance sheet?

MetLife's balance sheet shows $355M in debt, but true obligations total approximately $5.4B. The components: junior subordinated debentures of $3.17B face value with maturities in 2036-2039 at 6.4-7.875% rates; pension underfunding of $887M ($8,440M obligation vs $7,553M plan assets); approximately $1.0B in unfunded nonqualified pension plans; and undisclosed commitments to Chariot Holding Company, a Bermuda-registered limited partnership. While $5.4B is meaningful, it represents 19% of $28.4B equity and is manageable against $17.1B in annual operating cash flow.

What does MetLife's $25B free cash flow target mean for shareholders?

Management targets approximately $25B in free cash flow over 2025-2029, with FY2025 achieving an 82% FCF-to-adjusted-earnings ratio — above the 65-75% target. At the $52.8B market cap, this implies approximately 9.5% annual FCF yield. MetLife returned $4.4B in FY2025 ($1.51B dividends + $2.88B buybacks), yielding 8.3% total shareholder return. However, the FCF ratio jumps to 126% when including $1.2B from "other holding companies" — a $1.22B swing from negative $23M in 2024 that is unexplained and should be viewed skeptically.

How sensitive are MetLife's earnings to interest rates?

The filing provides explicit plus or minus 50bps scenarios: a 50bps decline reduces adjusted earnings by -$38M in 2026, -$97M in 2027, and -$148M in 2028 (cumulative -$283M, approximately 4.6% of adjusted earnings). A 50bps rise improves earnings by +$44M, +$108M, and +$146M (cumulative +$298M). The GAAP impact is far larger: net derivative losses swing by -$253M to +$255M in a single year. Additionally, the LTC business "experiences gross margin compression as we cannot reduce interest crediting rates for established claim reserves," creating an embedded put option on interest rates that MetLife wrote decades ago.

What are the biggest risks the 10-K reveals that aren't in the earnings call?

Three risks stand out: (1) Variable investment income dependency — $1.6B target (26% of adjusted earnings) assumes 9% PE returns; a miss to 5% could cost approximately $700M. (2) Corporate and Other losses tripled from -$117M to -$293M, with LTC margin compression as the likely driver — the fastest-deteriorating line item buried outside operating segments. (3) Chariot Holding Company — a Bermuda-registered limited partnership with redacted amounts, unfunded commitments, and a subsidiary that both reinsures MetLife and has its assets managed by MIM — a multi-layered related-party structure with zero dollar transparency.

What would make MetLife a value trap vs. a value opportunity?

The 8.9x adjusted P/E requires two conditions to hold: (1) Variable investment income must deliver near the $1.6B target — if PE returns average 5% instead of 9%, adjusted EPS drops from approximately $8.89 to approximately $7.85, inflating P/E to 10.3x. (2) Corporate and Other losses must stabilize near -$293M — continuation toward -$450M+ means the adjustment bridge is degrading. If both conditions fail simultaneously, adjusted earnings could decline 10-15%, turning a "cheap" P/E into fair value for a shrinking base. If both hold, the 8.3% yield and 9.5% FCF yield make MetLife one of the most attractive capital return stories in insurance.

Is MetLife's 82% FCF ratio sustainable?

The 82% FCF-to-adjusted-earnings ratio beat management's 65-75% target and improved from 79% in 2024. However, when including "other MetLife holding companies," the ratio jumps to 126% due to a $1.2B cash inflow that swung from -$23M the prior year. This $1.22B swing could represent captive reinsurance dividends, international holding company distributions, or Chariot-related cash flows. The core 82% ratio is likely sustainable based on MetLife's insurance float model, but the 126% ratio includes a volatile, unexplained source that should not be capitalized.

Methodology

Data Sources

This analysis draws on three primary data sources:

• SEC Filing: MetLife, Inc. FY2025 10-K (filed 2026-02-19). All filing-sourced numbers are tagged [FILING] in the research notes and verified against specific sections (MD&A, segment footnotes, pension footnotes, related-party disclosures). Filing sections read: risk_factors (30 chunks), mda_results_operations (21 chunks), mda_liquidity (21 chunks), footnote_segment (11 chunks), footnote_debt (3 chunks), footnote_accounting_policies (5 chunks), footnote_related_party (1 chunk), footnote_pension (5 chunks).
• MetricDuck Pipeline: Automated metrics from XBRL extraction covering revenue, margins, returns, valuation multiples, per-share data, and segment financials (155+ metrics). Cross-checked against filing figures; all Tier A findings upgraded from [PIPELINE] to [FILING] or [DERIVED] source tags.
• Peer Data: Aflac (AFL) core financials from FY2025 10-K (filed 2026-02-25, 151+ metrics). The brief's assigned peer list (FCAP, LARK, GLD, SAN) does not include true insurance comparables and is not used for sector analysis. PRU, LNC, UNUM, and MFC — ideal peers — lack extracted data in the pipeline.

Limitations

• Peer comparison is incomplete. Only AFL has full FY2025 data among insurance peers. PRU, LNC, UNUM, and MFC would provide better multi-peer benchmarks but lack pipeline extraction.
• MIM organic growth rate cannot be precisely calculated. The filing confirms fee agreements were repriced to market rates but does not disclose the dollar value of repricing versus organic growth. The 29.4% is an upper bound.
• Variable investment income sensitivity is estimated. The approximately $700M risk at 5% PE returns is a rough proportional estimate, not a management-provided scenario. The actual relationship between PE returns and variable investment income is nonlinear.
• Corporate & Other driver is inferred. The filing discloses both LTC margin compression and the -$293M loss, but does not explicitly link them. Strategic Reorganization cost reallocation is an alternative explanation.
• Chariot Holding Company amounts are redacted. Investment amounts, unfunded commitments, and reinsurance volumes are all stated as "$__ million" in the filing. Materiality cannot be assessed.
• Expense ratio current level is unknown. Management targets 12.1% for 2026 but the current direct expense ratio is not disclosed, so the starting point for the 80bps improvement target cannot be verified.

Disclaimer:

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in MET or AFL. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.